FDA warns on Bayer's Trasylol

Williams, Dede; Gibson, Jane
October 2006
ICIS Chemical Business;10/9/2006, Vol. 1 Issue 38, p10
Trade Publication
This article reports on warnings given by the U.S. Food and Drug Administration public advisory committee about Bayer's cardiovascular drug Trasylol due to negative side effects. The committee also warned physicians to carefully monitor patients for the occurrence of toxicity. The drug is a broad spectrum proteinase inhibitor used in heart bypass surgery. The agency has been conducting a risk-benefit analysis of Trasylol.


Related Articles

  • REGULATION. Franz, Neil // Chemical Week;12/13/2000, Vol. 162 Issue 46, p8 

    Focuses on a hearing requested by Bayer company to the United States Food and Drug Administration to protest the agency's proposal to ban fluoroquinolone poultry antibiotics. Details on Bayer's review of Baytril; Health and environmental organizations pressuring Bayer to pull Baytril from the...

  • Gender Differences with Anticoagulation Discontinuation.  // Travel Medicine Advisor;Oct2008, Vol. 18 Issue 10, p1 

    The article presents an update related to pharmacology as of October 2008. A study by Canadian researchers suggests that women with minimal risk factors may safely stop anticoagulation after six months of therapy, although this does not apply to men. The U.S. Food and Drug Administration (FDA)...

  • FDA Actions.  // Travel Medicine Advisor;Oct2008 Supplement, p2 

    The article cites the warnings issued by the U.S. Food and Drug Administration in October 2008. The warnings involved the use of simvastatin by patients taking amiodarone because of the risk of rhabdomyolysis and the use of exenatide and the risk of acute pancreatitis. The flu vaccine is a...

  • US FDA warns of increased myopathy risk with Zocor.  // Reactions Weekly;3/27/2010, Issue 1294, p1 

    This article deals with the warning issued by the U.S. Food and Drug Administration to both healthcare professionals and patients regarding the increased risk of muscle injury associated with the highest approved dose of simvastatin.

  • US FDA reviewing safety of ezetimibe/simvastatin.  // Reactions Weekly;8/30/2008, Issue 1217, p2 

    The article reports on the safety review by the U.S. Food and Drug Administration (FDA) of ezetimibe (Vytorin) and simvastatin after receiving a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial about a possible association between ezetimibe use and increased cancer risk....

  • Door opens for return of Vioxx to the US market.  // Reactions Weekly;2/26/2005, Issue 1040, p2 

    Focuses on the decision of the U.S. Food and Drug Administration's joint Arthritis Drugs/Drug Safety and Risk Management Advisory Committee to continue selling cardiovascular agents Merck's Vioxx, Bextra and Celebrex in the country in 2005. Vote of the joint Committee in favor of the continued...

  • Statins do not increase the risk of amyotrophic lateral sclerosis.  // Reactions Weekly;10/11/2008, Issue 1223, p3 

    The article focuses on an analysis by the U.S. Food and Drug Administration (FDA) which revealed that statins does not appear to increase the risk of amyotrophic lateral sclerosis (ALS). Data mining signal for ALS and statins were evaluated by the FDA in its Adverse Event Reporting System...

  • AstraZeneca: PR warfare.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p12 

    Reports on Public Citizen's call for the U.S. Food and Drug Administration to investigate AstraZeneca's cholesterol drug, Crestor or rosuvastatin calcium. Prescription growth of Crestor despite negative publicity on the drug; Call for investigation on whether AstraZeneca delayed the disclosure...

  • Safety Alerts Cite Cholesterol Drugs' Side Effects.  // MondayMorning;3/5/2012, Vol. 20 Issue 10, p1 

    The article presents information on the safety alerts that have been issued by the U.S. Food and Drug Administration regarding the side effects of statins, which are drugs commonly prescribed to reduce cholesterol levels. As stated, the side effect risks include cognitive problems such as memory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics